ArticleAmerican journal of translational research2026
Long non-coding RNA ZBTB46-AS1 promotes ovarian cancer progression through regulation of p53 activity by TAF6 protein.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the oncogenic role and molecular pathways associated with long non-coding RNA ZBTB46-AS1 (lncRNA ZBTB46-AS1) in ovarian cancer (OC) progression.
methodsBioinformatics analyses of the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were used to assess ZBTB46-AS1 expression and prognostic value. Quantitative real-time polymerase chain reaction (qRT-PCR) verified its expression in 22 pairs of OC and adjacent normal tissues, as well as OC cell lines. In vitro functional assays [Cell Counting Kit-8 (CCK8), colony formation, Transwell] and in vivo models [xenograft, lung metastasis] were performed to evaluate the effects of ZBTB46-AS1 knockdown. RNA pull-down, RNA immunoprecipitation (RIP), dual-luciferase reporter, and co-immunoprecipitation (Co-IP) assays clarified its interaction with TATA-box-binding protein-associated factor 6 (TAF6) and tumor suppressor protein p53.
resultsZBTB46-AS1 was significantly upregulated in OC tissues and cell lines, correlating with poor overall survival (OS) of patients. Stable knockdown of ZBTB46-AS1 inhibited the proliferation, colony formation, and epithelial-mesenchymal transition (EMT) of OC cells in vitro, as well as tumor growth and distant metastasis in vivo. Mechanistically, ZBTB46-AS1 directly interacted with TAF6, which attenuated the binding between TAF6 and p53, suppressed p53 transcriptional activity, and consequently downregulated the expression of p21. Notably, co-silencing of ZBTB46-AS1 and p53 effectively reversed the inhibitory effects induced by ZBTB46-AS1 knockdown on OC cell malignant phenotypes.
conclusionZBTB46-AS1 promotes OC progression via the TAF6-p53 axis, serving as a potential prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.